Introduction
Evidence for the potential role of adenosine in the pathogenesis of asthma has been growing steadily since the early observation of its bronchoconstrictor effect in human asthmatics. In the early 1980s, it was shown that adenosine or AMP (which is converted to adenosine in vivo by 5 / -nucleotidase) induces bronchoconstriction in asthmatics but not in normal subjects (Cushley et al., 1983) . In contrast to methacholine, which induces changes in airway caliber, AMP-induced bronchial hyperresponsiveness (BHR) is proposed to be related to the inflammatory status of the asthmatic lung (Spicuzza L et al., 2003) . Adenosine has also been shown to increase the concentrations of mediators released from mast cells, such as histamine, tryptase, LTC 4 and PDG 2 (Crimi et al, 1997) .
Adenosine-induced bronchoconstriction is attenuated by drugs that either inhibit mast cell activation or serve as antagonists to the mediators released from the mast cells (Holgate, 2005) . Thus, a potential mechanism by which adenosine causes bronchoconstriction is mast cell activation (Polosa et al., 2002; Holgate, 2005) . In addition, it has been shown that the concentration of adenosine in the bronchoalveolar lavage fluid (BALF) of patients with asthma is higher than that in non-asthmatics (Driver et al. 1993 ). Higher concentrations of adenosine were detected in the exhaled breath condensate of atopic asthmatics as compared to those of nonatopic controls (Huszar et al., 2002) . Hence, adenosine may function as a paracrine mediator of the inflammatory responses in the lung.
The effects of adenosine are mediated through a family of cell surface G-protein coupled receptors, which are currently classified into four adenosine receptor subtypes: (Feoktistov and Biaggioni, 1995; Feoktistov et al., 2001; Ryzhov et al., 2004) and these cytokines can induce IgE synthesis by B lymphocytes (Ryzhov et al., 2004) . Similarly, adenosine activation of A 2B AR increases the release of inflammatory cytokines from human bronchial smooth muscle cells, human lung fibroblasts, and human airway epithelial cells (Zhong et al., 2004; Zhong et al., 2005) . These cytokines, in turn, induce differentiation of lung fibroblasts into myofibroblasts (Zhong et al., 2005) and, increase the release of TNFα from monocytes (Zhong et al., 2006) . These effects of adenosine have been shown to be inhibited by selective antagonists of the A 2B AR (Feoktistov and Biaggioni, 1995; Feoktistov et al., 2001; Ryzhov et al., 2004; Zhong et al., 2004; Zhong et al., 2005; Zhong et al., 2006) . Thus, A 2B ARs may play an important role in the pathophysiology of asthma.
The allergic mouse model developed and characterized in this laboratory has been used to further understand the role of adenosine and its receptors in airway reactivity and inflammatory (Fan and Mustafa, 2002; Fan and Mustafa, 2006) . The previously described features of this model are: 1) aerosolized adenosine causes a concentration-dependent bronchoconstriction, measured as Penh in sensitized mice; and 2) aerosolized adenosine potentiates the allergen-induced airway inflammation and both of these effects are This article has not been copyedited and formatted. The final version may differ from this version.
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CVT-6883 is a specific and selective antagonist to the A 2B AR. Its binding affinities for the four subtypes of ARs were determined using competition radioligand binding assays in membranes isolated from cell lines that over-express each of the four ARs (Sun et al, 2006) . The aims of this study were to determine the effect of CVT-6883:
1) on the airway reactivity induced by aerosolized NECA, AMP or allergen and 2) on the numbers of inflammatory cells in BALF after allergen challenge.
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Methods
Animals
Male BALB/c mice, 6 to 8 wk of age and free of specific pathogens, were obtained from
Harlan Laboratories (Indianapolis, IN). The animals were maintained on a ragweed-free diet. All experimental animals used in this study were under an approved protocol from the Institutional Animal Care and Use Committee of East Carolina University.
Chemicals and Reagents
Ragweed pollen extract was purchased from Greer Laboratories (Lenoir, NC DMSO/saline (25/75, v/v) .
Experimental Protocols
Sensitization and challenge with ragweed
Sensitization and challenge with ragweed (SENS) or saline (control) were performed according to a method described previously (Fan and Mustafa, 2002; Fan and Mustafa, 2006 
Measurement of airway reactivity
On Day 14, mice were challenged with NECA, AMP or allergen and the airway reactivity was measured using barometric plethysmography (Fan and Mustafa, 2002; Oldenburg and Mustafa, 2005, Fan and Mustafa, 2006) . It has been previously shown that changes (increases or decreases) in Penh correlate with changes (increases or decreases) in airway resistance in this model (Justice et al., 2001) .
NECA challenge
Mice sensitized and challenged with ragweed (SENS) were used in this study. mice were placed in the Plexiglas chambers and exposed to the nebulization vehicle (saline) or increasing concentrations of AMP (6, 12 and 24 mg/ml in saline) for 2 min.
The remaining procedure was same as described above for NECA challenge. Airway reactivity was expressed as percentage increase in Penh compared to the nebulization vehicle (saline).
Allergen challenge: airway reactivity
Both control mice (control, sensitized and challenged with saline) and sensitized mice (SENS, sensitized and challenged with ragweed) were used in this study. There were three groups: control mice treated with the vehicle (DMSO/saline, 25/75, v/v), sensitized mice treated with the vehicle or CVT-6883 (1 mg/kg, i.p.). On day 14, the vehicle or CVT-6883 was given 60 min prior to allergen challenge. For allergen challenge, mice were placed in Plexiglas chambers and exposed to either 5% of ragweed or saline for 10 min with a DeVilbiss nebulizer (Somerset, PA) at 2.0 ml/min and the aerosol particles had a median aerodynamic diameter of less than 4 µm. Penh was recorded for 5 h with This article has not been copyedited and formatted. The final version may differ from this version.
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Allergen challenge: inflammatory cells in the bronchoalveolar lavage fluid (BALF)
Both control mice (control, sensitized and challenged with saline) and sensitized mice (SENS, sensitized and challenged with ragweed) were used in this study. There were four groups: control mice or sensitized mice treated with the vehicle, CVT-6883 (6 mg/ml, aerosol for 5 min) or theophylline (36 mg/ml, aerosol for 5 min). The dose of theophylline was chosen based on our previous work (Fan and Mustafa, 2002) and the dose of CVT-6883, 6 mg/ml, was the highest soluble concentration in the vehicle. On day 14, fifteen minutes after administration of CVT-6883 or theophylline, mice were exposed to either 2% of ragweed or saline for 10 min with a DeVilbiss nebulizer (Somerset, PA) at 2.0 ml/min and the aerosol particles had a median aerodynamic diameter of less than 4 µm.
Five hours after the allergen challenge, BALF were collected and analyzed to assess airway inflammation. Mice were killed using i.p. injection of 0.1 ml pentobarbitone sodium (200 mg/ml). The trachea was cannulated to introduce 0.8 ml phosphate-buffered saline (PBS) into the lungs three times, followed by centrifugation at 1500 rpm for 6 min at 4°C (Beckman, Model TJ-6 centrifuge). After removing the supernatant, the BALF cells were re-suspended in 1 ml of PBS. The total cells were then counted manually in a hemocytometer chamber. Cells were spun onto glass slides (Cytospin 3, Cytospin, to standard morphologic criteria. The number of cells recovered per mouse were calculated and expressed as mean ± SEM/ml for each group.
Statistical Analysis
Data are expressed as mean ± SEM. Data were analyzed by Analysis of variance (ANOVA) followed by Tukey's test for multiple comparisons. Paired t-test was utilized for calculating difference in Penh values before and after different drug treatments. A p value of <0.05 was considered statistically significant.
Results
Effect of CVT-6883 on NECA-induced Increases in Penh
The effect of CVT-6883 on NECA-induced airway reactivity in mice that were sensitized and challenged with ragweed (SENS) was determined. As shown in 
Effects of CVT-6883 and Montelukast on AMP-induced Penh Increase
The effects of CVT-6883 and montelukast on AMP-induced airway reactivity were determined. As shown in Figure 2 , aerosolized AMP increased Penh values in a concentration-dependent manner in mice that were sensitized and challenged with ragweed (SENS) (Fig. 2b) but not in mice that were sensitized and challenged with saline (control) (Fig. 2a) .
In sensitized mice that were treated with vehicle, the increases in Penh (% of nebulization vehicle) induced by AMP (6, 12 and 24 mg/ml) were 116.60 + 13.41, 180.68 + 34.93 and 561.49 + 269.93%, respectively (n = 8). Treatment (15 min prior to AMP challenge) with either CVT-6883 (1 mg/kg, i.p.) or montelukast (1 mg/kg, i.p.) attenuated the AMPinduced increases in Penh. The AMP-induced increases in Penh in the SENS+vehicle group was significantly greater than increases in Penh in SENS+CVT-6883 group (12 and 24 mg/ml AMP) or SENS+montelukast group (6, 12, and 24 mg/ml AMP) (p < 0.05, ANOVA).
Effect of CVT-6883 on Late Allergic Response
The effect of CVT-6883 on the airway reactivity induced by allergen in the SENS mice was also determined. As shown in Figure 3 allergen challenge) with CVT-6883 (1 mg/kg, i.p.) attenuated this late allergic response (Fig. 3 a, top panel) .
To quantify this late allergic response, the area under the Penh-time curve (AUC) was calculated for the whole 5 h period as well as for late allergic response that occurred between 3-4 h after allergen challenge. The percent (%) increases in AUC 3-4h for
SENS+vehicle and SENS+CVT-6883 groups were approximately 106 % and 7 %, respectively as compared to control (n = 8, Fig. 3c ). The AUC 0-5h (Fig. 3b) and AUC 3-4h ( Fig. 3c ) value of the SENS+vehicle group was significantly higher than that of control group which was attenuated by treatment with CVT-6883 in sensitized group (SENS+CVT-6883) only in AUC 3-4h (p < 0.05, ANOVA) as shown in Fig. 3 (c) .
Effect of Aerosolized CVT-6883 and Theophylline on Allergen-induced Increases in the Number of the Inflammatory Cells in BALF
The effect of CVT-6883 on allergen-induced increases in the number of inflammatory cells in BALF obtained from sensitized mice was determined. As shown in Figure 4 antagonist, or MRS 1523, a selective A 3 antagonist. In allergic guinea pig model, it was reported that A 1 agonist CPA induces airway obstruction by a neuronal-dependent mechanism whereas A 2A agonist CGS 21680 or A 3 agonist IB-MECA has no effect (Keir et al, 2006) . Interestingly, it was also reported that A 3 agonist IB-MECA could contract sensitized guinea pig trachea (Martin and Broadley, 2002) . In allergic rabbit model, adenosine-induced contractions of tracheal and bronchial smooth muscles are mainly due to the activation of A 1 receptors on rabbit smooth muscle (Ali et al, 1994 ). In this model, A 1 antagonist L-97-1 seems to be effective in blocking adenosine-induced bronchoconstriction (Obiefuna et al, 2005) . Obviously, different receptor subtypes have been implicated in airway reactivity depending on the animal models.
In the present study, similar to human, AMP challenge caused increase in airway reactivity in mice that were sensitized and challenged by ragweed but not in shamsensitized/challenged mice. In addition, the AMP-induced airway reactivity was bronchoconstriction, eosinophilia and mucus production (Tilley et al, 2003; Fan et al, 2003; Ramkumar et al, 1993) . A study in human asthmatics showed an increase in the expression of A 3 ARs in lung biopsies of patients with asthma, which were mostly located on eosinophils. In addition, it was suggested that A 3 ARs were also involved in inhibition of chemotaxis (Walker et al, 1997) .
On the other hand, animal and human studies suggest an important role for A 2B AR in mediating airway reactivity and inflammatory responses in the lung (Holgate, 2005; Polosa, 2002) . Expression of adenosine A 2B receptors has been found in bronchial epithelium (Clancy et al, 1999) , in cultured human airway smooth muscle (Mundell et al, 2001 ), in human mast cells (Marquardt et al, 1994) , monocytes (Zhang et al, 2005) and fibroblasts (Zhong et al, 2005) . The NECA-induced increase in airway reactivity was partially blocked by enprofylline, a relatively selective A 2B antagonist (Fan et al, 2003) . This article has not been copyedited and formatted. The final version may differ from this version.
